GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Torrent Pharmaceuticals Ltd (NSE:TORNTPHARM) » Definitions » EV-to-EBIT

Torrent Pharmaceuticals (NSE:TORNTPHARM) EV-to-EBIT : 36.53 (As of May. 15, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Torrent Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Torrent Pharmaceuticals's Enterprise Value is ₹925,781 Mil. Torrent Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₹25,344 Mil. Therefore, Torrent Pharmaceuticals's EV-to-EBIT for today is 36.53.

The historical rank and industry rank for Torrent Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

NSE:TORNTPHARM' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.2   Med: 23.09   Max: 40.52
Current: 36.53

During the past 13 years, the highest EV-to-EBIT of Torrent Pharmaceuticals was 40.52. The lowest was 9.20. And the median was 23.09.

NSE:TORNTPHARM's EV-to-EBIT is ranked worse than
79.16% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.74 vs NSE:TORNTPHARM: 36.53

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Torrent Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was ₹780,302 Mil. Torrent Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₹25,344 Mil. Torrent Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 3.25%.


Torrent Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Torrent Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Torrent Pharmaceuticals EV-to-EBIT Chart

Torrent Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.63 23.58 25.15 34.31 26.00

Torrent Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.70 26.00 28.96 29.36 30.79

Competitive Comparison of Torrent Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Torrent Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Torrent Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Torrent Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Torrent Pharmaceuticals's EV-to-EBIT falls into.



Torrent Pharmaceuticals EV-to-EBIT Calculation

Torrent Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=925781.497/25344
=36.53

Torrent Pharmaceuticals's current Enterprise Value is ₹925,781 Mil.
Torrent Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹25,344 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Torrent Pharmaceuticals  (NSE:TORNTPHARM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Torrent Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=25344/780301.86975
=3.25 %

Torrent Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was ₹780,302 Mil.
Torrent Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹25,344 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Torrent Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Torrent Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Torrent Pharmaceuticals (NSE:TORNTPHARM) Business Description

Traded in Other Exchanges
Address
Off Ashram Road, Torrent House, Ahmedabad, GJ, IND, 380009
Torrent Pharmaceuticals Ltd is a drug manufacturing company with a focus on the cardiovascular, central nervous system, and gastrointestinal therapeutic areas. It operates through Generic Formulation Business segments. Geographically, the business activities are carried out across Indian and International markets.

Torrent Pharmaceuticals (NSE:TORNTPHARM) Headlines

No Headlines